Conferences  >  Medicine & Healthcare  >  Hematology  >  United States

Binaytara Foundation

This CME-accredited activity Cellular Therapy in Hematology and Oncology: Expert Guidance for Clinical Practice features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Phone: [425-616-0572];     Email: cme@binayfoundation.org

Cellular Therapy, Oncology, Hematology, Lymphoma, Myeloma, Acute Leukemia

Oncology,    Continuing Medical Education (CME)

Binaytara Foundation

This CME-accredited activity, Park City Lymphoma Myeloma Conference, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Phone: [425-616-0572];     Email: cme@binayfoundation.org

Oncology, Hematology, Lymphoma, Myeloma, Waldenström Macroglobulinemia

Continuing Medical Education (CME),    Oncology

Binaytara Foundation

This CME-accredited activity, the 2024 Annual Summit on Hematologic Cancers, is a national meeting featuring leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Phone: [425-616-0572];     Email: cme@binayfoundation.org

Hematology, Oncology, CME, Cancer